Dr. Ryan Lynch, MD
Claim this profileFred Hutch/University of Washington Cancer Consortium
Area of expertise
Non-Hodgkin's Lymphoma
Ryan Lynch, MD has run 5 trials for Non-Hodgkin's Lymphoma.
Hodgkin's Lymphoma
Ryan Lynch, MD has run 4 trials for Hodgkin's Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Fred Hutch/University Of Washington Cancer Consortium
Seattle Cancer Care Alliance / University Of Washington
Clinical Trials Ryan Lynch, MD is currently running
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Recruiting
1 award
Phase 2
5 criteria
Personalized Chemotherapy
for Hodgkin's Lymphoma
This phase II trial tests how well personalized reduction of chemotherapy (nivolumab, doxorubicin, vinblastine and dacarbazine) based on circulating tumor deoxyribonucleic acid (ctDNA) evaluation works for treating patients with Hodgkin lymphoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Chemotherapy drugs, such as nivolumab, doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Many types of tumors tend to lose cells or release different types of cellular products including their DNA, which is referred to as ctDNA, into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids and, based on the result, assign patients to a reduced number of chemotherapy treatments or the standard number of chemotherapy treatments. Using ctDNA to assign a personalized reduction of chemotherapy may be effective in treating patients with advanced Hodgkin lymphoma.
Recruiting
1 award
Phase 2
5 criteria
More about Ryan Lynch, MD
Clinical Trial Related
6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Ryan Lynch, MD has experience with
- Dacarbazine
- Doxorubicin
- Rituximab
- Nivolumab
- Vinblastine
- Polatuzumab Vedotin
Breakdown of trials Ryan Lynch, MD has run
Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Cutaneous T-Cell Non-Hodgkin Lymphoma
Follicular Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ryan Lynch, MD specialize in?
Ryan Lynch, MD focuses on Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma. In particular, much of their work with Non-Hodgkin's Lymphoma has involved treating patients, or patients who are undergoing treatment.
Is Ryan Lynch, MD currently recruiting for clinical trials?
Yes, Ryan Lynch, MD is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Ryan Lynch, MD has studied deeply?
Yes, Ryan Lynch, MD has studied treatments such as Dacarbazine, Doxorubicin, Rituximab.
What is the best way to schedule an appointment with Ryan Lynch, MD?
Apply for one of the trials that Ryan Lynch, MD is conducting.
What is the office address of Ryan Lynch, MD?
The office of Ryan Lynch, MD is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.